From research to patient access
Psychedelic therapies are moving from clinical trials toward healthcare systems — but the path is complex. We break down the science, regulations, economics, and barriers shaping how these treatments reach the people who need them, with a focus on Europe and the United States.
The Big Picture
Landscape overview of psychedelic therapy implementation, key takeaways, and future outlook across Europe and the US.
Where do psychedelic therapies stand today? This section provides a landscape overview of the implementation journey — from research labs to healthcare systems. We cover the key milestones reached so far, what the evidence tells us about where things are heading, and what the path forward looks like across Europe and the United States.
The Science
Drug development stages, clinical trial phases, and the evidence base underpinning psychedelic therapies.
Before any therapy reaches patients, it must pass through rigorous clinical development. Here we break down the drug development pipeline for psychedelic therapies: preclinical research, Phase I–III trials, the growing evidence base, and what the clinical data actually shows about efficacy and safety. We draw directly on the research papers in our database to go deeper.
Regulatory Pathways
Approval processes, regulatory frameworks, and how different regions are approaching psychedelic therapy authorization.
How do psychedelic therapies get approved? Regulatory frameworks differ dramatically between the US (FDA), Europe (EMA), and individual countries. This section maps out the approval processes, breakthrough therapy designations, compassionate use programs, and the regulatory innovations being explored to bring these treatments to market.
Who Pays
Health economics, health technology assessment, reimbursement models, and insurance coverage for psychedelic therapies.
Even after approval, a therapy only reaches patients if someone pays for it. This is where health economics meets policy. We explore health technology assessment (HTA), cost-effectiveness analyses, reimbursement models, insurance coverage decisions, and the economic case for psychedelic therapies. Expect deep dives into payer perspectives, QALY calculations, and interviews with health economists.
Barriers & Challenges
Stigma, supply chain constraints, training requirements, and political hurdles standing in the way of implementation.
The road to implementation is full of obstacles. Stigma, scheduling restrictions, therapist training bottlenecks, supply chain constraints, intellectual property tensions, and political resistance all play a role. This section maps the barriers — both the obvious ones and the structural challenges that are harder to see.
Solutions & Models
Innovative approaches, therapy delivery models, and policy recommendations for advancing psychedelic therapy access.
What's actually working? From group therapy models that improve cost-effectiveness, to digital therapeutics that extend access, to policy frameworks from pioneering jurisdictions — this section highlights the innovative approaches being developed. We cover delivery models, training programs, regulatory sandboxes, and the policy recommendations emerging from researchers and practitioners.
Access & Equity
Global access considerations, underserved populations, equitable distribution, and emerging pathways to broad availability.
Who gets access — and who gets left behind? As psychedelic therapies move toward approval, questions of equity become urgent. This section examines global access disparities, affordability, underserved populations, Indigenous knowledge and reciprocity, and the emerging pathways to ensure these treatments don't become available only to the privileged few.